01—Abstract
Summary
Summary of the 8-K filed October 6, 2026. Cited figures are marked; the original filing is the authoritative source.
On October 6, 2026, Stryker (NYSE: SYK) announced a planned CEO succession.
Kevin Lobo, CEO since October 2012 and Chair since July 2014, will step down as CEO on December 31, 2026 and become Executive Chair of the Board effective January 1, 2027. Spencer Stiles, the company's President and COO since January 2026, will succeed him as CEO on the same date and join the Board, which expands from 10 to 11 members. The Board frames the change as the culmination of a long-term succession process, and Lobo's transition agreement keeps his base salary, bonus target and benefit eligibility unchanged, though he will receive no new stock awards as Executive Chair.
For Stiles, the 8-K sets a base salary of $1,320,000a and a bonus target of 150% of base salary from January 1, 2027. The Board will also be asked to approve a February 2027 equity grant with an aggregate target grant date fair value of $14.2 million, split 40% stock options and 60% performance stock units. Investors should note that the filing does not specify a stock option strike price methodology or exercise terms beyond the standard five-year annual vesting for options, and it discloses no committee assignments for Stiles yet.
The transition is planned and orderly, with a seven-month handover period before the effective date. The key open questions for investors concern continuity of strategy and execution under new leadership, retention of key personnel, and whether the Executive Chair role leaves Lobo with meaningful influence over the company's direction. The press release's forward-looking statements flag these execution and retention risks explicitly.
02—Key points
Key Highlights
- Kevin Lobo steps down as CEO on December 31, 2026 and becomes Executive Chair of the Board effective January 1, 2027, after 14 years as CEO.
- Spencer Stiles, currently President and COO and a nearly three-decade Stryker veteran, will become CEO effective January 1, 2027 and joins the Board, which expands from 10 to 11 directors.
- Stiles's base salary rises to $1,320,000 and his annual bonus target to 150% of base salary as CEO.
- The Board will recommend a February 2027 equity award to Stiles with an aggregate target grant date fair value of $14.2 million (40% stock options, 60% PSUs).
- Lobo's base salary, bonus target and benefit eligibility are unchanged under his Transition Agreement, but he will not receive new stock awards as Executive Chair.
- Under Lobo, net sales tripled from $8.7 billion in 2012 to more than $26 billion in 2026, with more than 60 acquisitions including Mako, and total shareholder return of over 450%, per company materials.
- No committee appointment for Stiles has been made yet, and the filing reports no related-party transactions or family relationships involving him.
03—Questions
Frequently Asked Questions
Is this CEO change happening immediately?
No. Lobo remains CEO through December 31, 2026, and Stiles takes over as CEO effective January 1, 2027. The change is planned, with a multi-month handover.
Will Kevin Lobo still play a role at Stryker?
Yes. Lobo will serve as Executive Chair of the Board starting January 1, 2027, with unchanged base salary, bonus target and benefit eligibility. He will not receive new stock awards in that role.
What is Spencer Stiles's compensation as CEO?
His base salary increases to $1,320,000 and his annual bonus target to 150% of base salary. The Board will also be asked to approve a February 2027 equity grant with a target grant date fair value of $14.2 million, split 40% stock options and 60% PSUs.
Why was Stiles chosen, and is there any related-party concern?
The Board cites his nearly three decades at Stryker, leadership across Orthopaedics, MedSurg and Neurotechnology, and his role in acquisitions such as Wright Medical. The filing states there are no arrangements with other persons for his selection, no family relationships with directors or executives, and no Item 404(a) related-party transactions.
What risks does the announcement highlight?
The press release's forward-looking statements cite the risk that Stiles and the executive team may not execute the strategy and business plans, and the risk of losing key personnel during and after the transition.
04—Continue